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TPR Total Peripheral Resistance 
TXA2  Thromboxane 
VSM Vascular Smooth Muscle 
VSMC  Vascular Smooth Muscle Cells 
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PENILAIAN AKTIVITI KARDIOVASKULAR DAN KAJIAN  KETOKSIKAN 
EKSTRAK KULIT KAYU ALSTONIA SCHOLARIS  
ABSTRAK  
 
Tujuan kajian ini adalah untuk memeriksa kesan antihipertensi ekstrak kulit kayu Alstonia 
scholaris (pulai) dan mekanisme tindakan farmakologinya. Pengekstrakan berturut-turut 
telah dijalankan untuk mendapatkan ekstrak metanol (ASME) dan air (ASWE) yang 
diperolehi selepas penyahlemakan dengan eter petroleum. Kesan antihipertensi ekstrak ini 
telah dinilai pada tikus hipertensi spontan (SHR). Pemberian ASME secara oral setiap hari  
(1000 mg/kg selama 2 minggu) mempamerkan penurunan ketara tekanan darah (p <0.05) 
tikus berbanding SHR kawalan. Melalui teknik fraksinasi cecair-cecair, ASME telah 
difraksikan berturut-turut menggunakan diklorometana, etil asetat dan n-butanol. Semua 
fraksi (0.125 – 4 mg/mL) menunjukkan vasorelaksi bergantung dos pada sediaan cincin aorta 
yang telah diprakontraksikan dengan fenileferina (PE; 1 µM) atau kalium klorida (80 mM). 
Fraksi n-butanol (NBF-ASME) merupakan fraksi yang paling poten (Rmax = 106.4 ± 0.045%). 
Prainkubasi cincin aorta dengan NBF-ASME (0.5, 1 dan 2 mg/mL) merencat tindak balas 
kontraksi cincin aorta yang diaruhkan PE dengan ketara (p <0.05-0.001). Pembuangan 
endotelium dan inkubasi dengan L-NAME, indometasin, atropina dan propranolol tidak 
menjejaskan dengan ketara relaksi oleh NBF-ASME. Tambahan pula, penghalang saluran 
K+, TEA menunjukkan sedikit aktiviti perencatan manakala glibenklamida tidak 
menunjukkan kesan perencatan. Walau bagaimanapun, cincin aorta yang diprarawat dengan 
ODQ menunjukkan perencatan keluk relaksi NBF - ASME dengan ketara (p < 0.01-0.001). 
Dalam larutan bebas Ca2+, NBF-ASME merencat pembebasan Ca2+ dalam sel dari retikulum 
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sarkoplasmik. NBF-ASME juga merencat kontraksi cincin aorta tidak berendotelium aruhan-
CaCl2 bergantung kepada kepekatan. Keputusan percubaan menunjukkan bahawa A. 
scholaris bertindak dengan menghalang saluran kalsium, mengaktifkan secara langsung 
enzim guanilat siklase dan mungkin juga merencat pembentukan inositol 1,4,5–trifosfat. 
Ketoksikan akut dan subakut ekstrak metanol A. scholaris (ASME) turut dinilai. Dalam 
kajian ketoksikan akut, dos tunggal ASME 2,000 mg/kg didapati tidak toksik. Manakala 
dalam kajian ketoksikan subakut tikus SD dari keuda-dua jantina telah diberikan tiga dos 
ASME (250, 500 dan 1000 mg/kg/hari) selama 28 hari. ASME 250 mg/kg tidak menunjukkan 
sebarang perbezaan yang signifikan dalam semua parameter berbanding dengan tikus 
kawalan. Beberapa perubahan ketara dari segi berat badan, hematologi dan parameter 
biokimia diperhatikan berlaku pada kumpulan tikus percubaan pada dos 500 dan 1000 mg/kg 
dengan dua kematian berlaku pada dos yang tertinggi. Kajian histopatologi menunjukkan 
berlaku sedikit degenerasi (lesion) dan nekrosis sentrilobular pada hati. Keputusan ini 
menunjukkan bahawa pemberian ASME secara oral setiap hari pada dos 500 mg/kg keatas 
adalah toksik dan mungkin fatal kepada haiwan terutamanya kerana kerosakan hati. 
  
xxiii 
 
EVALUATION OF THE CARDIOVASCULAR ACTIVITY AND TOXICITY 
STUDY OF ALSTONIA SCHOLARIS BARK EXTRACTS 
ABSTRACT 
 
The aim of the present study was to investigate the antihypertensive effect of Alstonia 
scholaris (pulai) bark extracts and its pharmacological mechanism of actions. Successive 
extraction was carried out to obtain methanol (ASME) and water (ASWE) extract of the bark 
after defatting with petroleum ether. The antihypertensive effect of these extracts were 
evaluated on spontaneous hypertensive rats (SHR). Daily oral administration of ASME (1000 
mg/kg for 2 weeks) exhibited a significant decrease in the blood pressure (p < 0.05) of the 
rats compared to control SHR. By means of liquid-liquid fractionation technique, the aqueous 
ASME solution was successively fractionated using dichloromethane, ethyl acetate and n-
butanol. All the fractions (0.125 – 4 mg/mL) gave a dose-dependent vasorelaxation on aortic 
ring preparations pre-contracted with phenylephrine (PE; 1 µM) or potassium chloride (80 
mM). The n-butanol fraction (NBF-ASME) was the most potent fractions (Rmax = 106.4 ± 
0.045 %). Pre-incubation of aortic rings with NBF-ASME (0.5, 1 and 2 mg/mL) significantly 
inhibit the contractile response of the aortic rings to PE-induced contraction (p<0.05-0.001). 
Removal of endothelium and incubation with L-NAME, indomethacin, atropine, and 
propranolol did not significantly affect the relaxation effect of NBF-ASME. Furthermore, of 
the K+ channel blockers, TEA showed slight inhibitory activity while glibenclamide showed 
no inhibitory effect. However, aortic rings pretreated with ODQ showed a significant 
suppression of the relaxation curve of NBF-ASME (p<0.01-0.001). In Ca2+-free solution, 
NBF-ASME inhibits the release of intracellular Ca2+ from the sarcoplasmic reticulum. NBF-
ASME also inhibits CaCl2-induced contraction in endothelium-denuded aortic rings in a 
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concentration-dependent manner. The result suggested that A. scholaris act via blocking 
calcium channels, direct activation of soluble guanylate cyclase and possibly by also 
inhibiting the formation of inositol 1, 4, 5-triphosphate. The acute and subacute toxicity of 
methanol extract of A. scholaris (ASME) was also evaluated. In the acute toxicity study, 
single dose of ASME 2,000 mg/kg was found to be non-toxic. In subacute toxicity study, SD 
rats of either sex were administered three doses of ASME (250, 500 and 1000 mg/kg/day) for 
28 days. ASME 250 mg/kg, did not produce any significant difference in all the parameters 
when compared to control rats. Some significant changes in body weight, hematological and 
biochemical parameters were observed in experimental groups of rats at the dose of 500 and 
1000 mg/kg with two animals died at the highest dose. Histopathological study revealed 
slight degeneration (lesion) and centrilobular necrosis in the liver. These results demonstrated 
that daily oral administration of ASME at 500 mg/kg and above is toxic and may be fatal to 
the animal primarily due to liver damage.. 
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1 CHAPTER 1: GENERAL INTRODUCTION 
1.1 Overview of the Cardiovascular System 
The cardiovascular system is the body’s transport system through which substances are 
conveyed and distributed from one part of the body to another via the circulation of the blood. 
The cardiovascular system, also referred to as circulatory system plays a vital role in 
sustaining life. It is responsible for the distribution of oxygen and nutrients to cells while 
removing carbon dioxide and other nitrogenous waste product. Its proper functioning is also 
responsible for maintaining an optimum pH, and the mobility of the elements, proteins and 
cells of the immune system. 
1.2 Components of the Cardiovascular System 
The cardiovascular system consists of the heart which serves as the pump, the arteries, veins 
and the capillaries that serve as the conducting tubes (blood vessels) and the circulating blood.  
1.2.1 The Heart 
The human heart, a hollow organ with a muscular structure, is situated slightly to the left of 
the thoracic cavity and is roughly the size of a man’s closed fist. It is responsible for 
propelling blood through the blood vessels by repeated contractions and relaxation 
synchrony. The heart is composed of a unique type of an involuntary muscle tissue called 
cardiac muscle, that is found only in this organ (Guyton and Hall, 2006). It is comprised of 
two pairs of chambers on the left and right side. Each side consists of an upper chamber 
known as atrium (plural; atria) and a lower chamber known as ventricle (plural; ventriculus) 
and functions as an independent pump. The two pumps are separated by a thick muscular 
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wall called septum which prevents the mixing of blood in the left and right sides of the heart. 
Connecting the atriums and ventricles are atrioventricular openings with valves that allow 
the passage of circulating blood from the atriums to the ventricles (Figure 1.1). The valves in 
the right atrium are referred to as tricuspid valves while those of the left are known to as 
bicuspid valves (Saladin, 2003). 
 
Figure 1.1: Anatomy of the frontal section of the heart’s cross-sectional view (Diagram 
adapted from McGraw-Hill companies.inc). 
 
The atrioventricular valves ensure the one-directional flow of blood from the atriums into the 
ventricles, thereby avoiding the backflow of circulating blood (Pappano and Wier, 2013). 
The right atrium receives blood coming into the heart from the blood vessels via the superior 
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and inferior vena cava and the left ventricle pumps blood out from the heart via the pulmonary 
arteries into the blood vessels. 
1.2.2 Conducting fluid (Blood) 
Blood consists of cellular elements (red blood cells, white blood cells, and platelets), plasma 
as well as the fluid in which the blood cells are suspended. The total normal circulating blood 
volume is approximately 8% of body weight (Guyton and Hall, 2006). Red blood cells are 
the most numerous cellular elements in the blood. They are produce from the bone marrow 
of the femur and are biconcave in shape. An integral structural component of the red blood 
cell is the hemoglobin, which confers on it the ability to bind oxygen molecules for 
transportation. The fluid portion of the blood, the plasma, is about 90% water and accounts 
for 55 to 60% of total blood volume. Proteins content of the blood is about 10% while other 
substances including hormones, enzymes, nutrient molecules, gases, electrolytes, and 
excretory products covers the remaining 2%. All of these substances are dissolved in the 
plasma (e.g., oxygen) or are colloidal materials (dispersed solute materials that do not 
precipitate out, e.g., proteins) (Tortora and Darrickson, 2006). 
1.2.3 Blood Vessels 
The blood vessels serve as the conducting tubules of the cardiovascular system. They form a 
close network of tubes, conveying the blood to all parts of the body organs in a unidirectional 
manner (Guyton and Hall, 2006).  
1.2.3.1 Structure of blood vessels 
A typical blood vessel consists of three layers of membrane tissues adapted for their 
biological function (Figure 1.2). The internal layer of tissue, called the tunica intima, 
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comprises of single layer of simple squamous epithelial cells with a small amount of 
supporting connective tissue. The middle layer of tissue, the tunica media, is made up of 
smooth muscle organized in a circular pattern with different layers of elastic tissue. The outer 
region of the blood vessel is made of collagen and elastic fibers and is called the tunica 
adventitia. Both arteries and veins have all three layers of tissue. However, the proportions 
of the three layers between arteries and veins differ dramatically (Saladin, 2003). 
1.2.3.2 Arteries and Arterioles 
Arteries are muscular blood vessels that convey both oxygenated and deoxygenated blood 
away from the heart. Blood flows from the right atrium into the right ventricle of the heart. 
From there it is pumped through the pulmonary arteries. The pulmonary arteries carries 
deoxygenated blood to the lungs where it is oxygenated. The oxygenated blood from the 
lungs returns into the left atrium of the heart through the pulmonary vein and advance to enter 
the right ventricle. The oxygenated blood from the right ventricle is pumped into large arteries 
called aorta which conveys the blood to the rest of the body. Arteries have a thick elastic wall 
that enable them withstand high pressure blood coming from the heart. 
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Figure 1.2: Structure and the layers of a typical blood vessel in the 
circulatory system (Diagram adapted from McGraw-Hill companies.inc). 
 
An arteriole is a small artery that extends and leads to capillaries. Arterioles have thick 
smooth muscular walls. These smooth muscles are able to contract (causing vessel 
constriction) and relax (causing vessel dilation). This contracting and relaxing affects blood 
pressure; the higher number of vessels dilated, the lower blood pressure will be. Arterioles 
are just visible to the naked eye (Pappano and Wier, 2013).  
1.2.3.3 Capillaries 
Capillaries are the smallest of a body’s vessels in the circulatory system; they connect arteries 
and veins, and most closely interact with tissues. They are very widespread in the body and 
have a  total surface area is approximately 6,300 square meters (Wang and Xing, 2010). 
Because of this, no cell is more than 50 micrometers away from capillaries. The walls of 
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capillaries are composed of a single layer of endothelium cells, which is lines the inner wall 
of all the vessels. Due to the very thin layer, molecules such as oxygen, water and lipids can 
move across the tissues by the process of diffusion. Waste products such as carbon dioxide 
and urea can diffuse back into the blood to be carried away for removal from the body 
(Masuda et al., 2012). 
1.2.3.4 Veins and venules 
Veins are the vessels that carry blood from the capillaries back into the heart. The small veins 
are called venules. The venules form the initial proximal part of the veins adjoined with the 
capillaries end. The venule branches link to form larger veins which eventually join to form 
the vena cava, the largest vein that supplies the heart. 
Structurally, the vein have the same three tissue layers as present in the arterial walls, 
however there are minor differences when compared to the arterial layers (Lawson and 
Weinstein, 2002). The inner endothelium layer of veins is smooth with protrusions at 
intervals that folded to form valves. The valves function to prevent backflow of blood and 
are more numerous in veins of the legs, where blood must often return to the heart against 
the gravitational force (Golledge and Quigley, 2003; Rutherford et al., 2000). The middle 
layer of veins consists of a thin layer of smooth muscle opposed to the thick layer found in 
arteries. It is thin because veins are less involve in the regulation of blood pressure and blood 
flow compare to the arteries. The outer layer of veins is also thin; not as much fibrous 
connective tissue is necessary because blood pressure in veins is very low (Scanlon and 
Sanders, 2007). 
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1.2.4 Vascular Smooth Muscle Cells (VSMC). 
The vascular smooth muscle cell (VSMC) forms an integral structural element of the blood 
vessels essentially involve in the regulatory processes of the vascular system (Aziz et al., 
2014). Smooth muscle arises from the mesenchyme at various sites in the embryo where 
smooth muscle ordinarily will occur in the adult (Furchgott, 2013; Worth et al., 2001). The 
undifferentiated cells in these areas continue to divide until they become confluent, after 
which individual cells, the myoblasts, differentiate. The myoblasts elongate and take on the 
fusiform shape characteristic of adult smooth muscle cells (Guo and Chen, 2012; Krause, 
2005). Smooth muscle cells are typically spindle shaped and vary in size from 20 μm (small 
blood vessels) to 400–500 μm (uterus), depending on site in the body. Each cell has a single, 
centrally located nucleus which is elongated or elliptical in shape. The VSM provides 
strategic vicinity in the blood vessels upon which both external and internal blood pressure 
regulatory factors exert their organic function. Impairment in this structure affects the overall 
cardiovascular system and is associated with numerous cardiovascular disease and 
dysfunction (Al-Sadi, 2012). 
1.2.4.1 Physiological Function of VSMC 
The vascular smooth muscle cell (VSMC) in mature animals is a highly specialized cell that 
perform the principal function of regulating the of blood vessel tone-diameter, blood 
pressure, and blood flow distribution (Aziz, et al., 2014). The smooth muscle cells (SMCs) 
constitute the predominant cellular component of the vascular media which respond to both 
external and internal physiological or pharmacological stimuli leading to vasoconstriction or 
dilation, syntheses of extracellular matrix (collagen, elastin and proteoglycans), elaboration 
and migration of  growth factors and cytokines into the intima  and cell proliferation and 
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regeneration after vascular injury (Curcio et al., 2011; Rzucidlo et al., 2007). These activities 
of SMCs are important in both normal vascular repair and pathological processes. The 
vascular system immensely depends on the modulation of the SMCs vasculature tone. 
1.2.4.2 The Contractile Elements in Smooth Muscles 
 Over the past decade, an acceptable understanding on the structural components involved in 
the contractile process of smooth muscle has been arrived at. Pile of experimental evidence 
has identified three major structural protein elements that are involve in the contractile 
process of the smooth muscle. The components include two types of filaments.  
1.2.4.2.1 Thick filaments: Myosin and the cross-bridge formation 
Myosin is the main protein of smooth muscle thick filaments. Each thick filament is made up 
of more than 200 myosin molecules. These are fibrous structures with globular ends. Myosin 
is composed of two heavy chain subunits, each about 200 kDa. The heavy subunits have two 
types of light chain subunits (20 and 17 kDa, respectively) protruding at given intervals. 
Phosphorylation of the 20 kDa light chain is vital in the initiation of the contractile process; 
the 17 kDa light chain function is not as clearly defined (Levine et al., 2001). 
The SMCs motor response is controlled by the sliding of myosin and actin filaments over 
each other (Cooke, 2004). The energy requirement for this process is provided by the 
hydrolysis of ATP. ATP is utilized by the myosin filament to cause molecular conformational 
changes in its own structure, which in turn facilitate its interaction with actin filaments, 
leading to the formation of cross-bridges (Hartel et al., 2007; Matsumura et al., 1999). The 
cross-bridge occurs when the extended globular heads in the myosin filaments interact with 
actin filaments. These heads lean on the actin filament and drag along to produce contraction. 
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The cross-bridges is halted when the actin and myosin filament detached from one another 
and returning to their original conformation which result in relaxation. This process is known 
as cross-bridge cycling and is considered to be common to all smooth muscles (Smolock et 
al., 2007). 
1.2.4.2.2 The Thin Filament: Actin and Tropomyosin 
Actin, which is the major component of the thin filament, is found in all mammalian cells. 
The chemical composition of actin from different sources may differ slightly. Actin is a 
fibrous molecule that forms the thin filament and is composed of two strands of 42 kDa 
globular actin molecules. The two functions of actin in the contractile process are: (1) 
transmission of force by the movement of the bridge of the myosin molecule against the actin 
and (2) activation of the myosin ATPase to generate free energy required for contraction 
(Regnier et al., 2004). Like actin, tropomyosin is a fairly ubiquitous molecule in all types of 
muscle with a molecular weight of about 70 kDa and is an alpha helix that is closely attached 
to the actin molecule in the thin filament. Furthermore, the ratio of tropomyosin to actin 
molecules (approximately 1:3) is similar in all types of muscle (Marston and El-Mezgueldi, 
2008).  
1.2.4.3 Excitation-Contraction Coupling in Smooth Muscle 
The mechanism of excitation-contraction coupling in smooth muscle differs from that of 
skeletal muscle. While in skeletal muscle binding of actin and myosin is permitted when 
Ca2+ binds troponin C; in smooth muscle, there is no troponin. Rather, the interaction of actin 
and myosin is controlled by the binding of Ca2+ to another protein, calmodulin. In turn, Ca2+-
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calmodulin regulates myosin-light-chain kinase, which regulates cross-bridge cycling 
(Costanzo, 2013). 
1.2.4.3.1 Smooth Muscle Contraction 
The steps involved in excitation-contraction coupling in smooth muscle bring about the 
contraction and relaxation of the smooth muscle cells and occur as follows: 
 Depolarization of smooth muscle opens voltage-gated Ca2+ channels in the 
sarcolemmal membrane. With the Ca2+ channels open, Ca2+ currents pass into the cell 
down its electrochemical gradient. This influx of Ca2+ from the extracellular fluid 
(ECF) causes an upsurge in intracellular Ca2+ concentration. In contrast to skeletal 
muscle, where action potentials are required to produce contraction, in smooth 
muscle, sub-threshold depolarization (which does not lead to an action potential) can 
open these voltage-gated Ca2+ channels and cause a rise in intracellular 
Ca2+ concentration. If the depolarization of the smooth muscle membrane reaches 
threshold, then action potentials can occur, causing even greater depolarization and 
even greater opening of voltage-gated Ca2+ channels. 
 Ca2+ that enters the smooth muscle cells through voltage-gated Ca2+ channels and 
stimulate the releases of additional Ca2+ from the sarcoplasmic reticulum (SR; 
called Ca2+-induced Ca2+ release). Consequently, the increase in intracellular Ca2+ is 
partly due to Ca2+ entry across the sarcolemmal membrane through either the voltage-
gate and partly due to the release of Ca2+ from the intracellular SR stores. 
 Two additional mechanisms may contribute to the increase in intracellular 
Ca2+ concentration: ligand-gated Ca2+ channels and inositol 1,4,5-triphosphate (IP3)–
gated Ca2+ release channels on the plasma membrane of SR. Ligand-gated 
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Ca2+ channels in the sarcolemmal membrane may be opened by various hormones 
and neurotransmitters, permitting the entry of additional Ca2+ from the ECF. IP3-
gated Ca2+ release channels in the membrane of the sarcoplasmic reticulum may be 
opened by hormones and neurotransmitters. Either of these mechanisms may augment 
the rise in intracellular Ca2+concentration caused by depolarization. 
 The rise in intracellular Ca2+ concentration causes Ca2+ to bind to calmodulin. Like 
troponin C in skeletal muscle, calmodulin binds four ions of Ca2+ in a cooperative 
fashion. The Ca2+-calmodulin complex binds to and activates myosin-light-chain 
kinase. 
 The myosin-light-chain kinase, when activated, phosphorylates myosin light chain. 
When myosin light chain is phosphorylated, the conformation of the myosin head is 
altered, greatly increasing its ATPase activity. (In contrast, skeletal muscle myosin 
ATPase activity is always high.) The increase in myosin ATPase activity allows 
myosin to bind to actin, thereby initiating cross-bridge cycling and production of 
tension. The amount of tension is proportional to the intracellular Ca2+ concentration. 
 Ca2+-calmodulin, in addition to the effects on myosin described earlier, also has 
effects on two thin filament proteins, calponin and caldesmon. At low levels of 
intracellular Ca2+, calponin and caldesmon bind actin, inhibiting myosin ATPase and 
preventing the interaction of actin and myosin. When the intracellular Ca2+ increases, 
the Ca2+-calmodulin complex leads to phosphorylation of calponin and caldesmon, 
releasing their inhibition of myosin ATPase and facilitating the formation of cross-
bridges between actin and myosin. 
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1.2.4.3.2 Smooth muscle relaxation 
Relaxation of smooth muscle occurs when the intracellular Ca2+ concentration falls below the 
level needed to form Ca2+-calmodulin complexes. A fall in intracellular Ca2+ concentration 
can occur by a variety of mechanisms including hyperpolarization (which closes voltage-
gated Ca2+ channels); direct inhibition of Ca2+ channels by ligands such as cyclic AMP and 
cyclic GMP; inhibition of IP3 production and decreased release of Ca2+ from sarcoplasmic 
reticulum; and increased Ca2+ ATPase activity in sarcoplasmic reticulum. Additionally, 
relaxation of smooth muscle can involve activation of myosin-light-chain phosphatase, which 
dephosphorylates myosin light chain, leading to inhibition of myosin ATPase (Figure 1.3). 
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Figure 1.3: Schematic illustration of the mechanisms contributing to vasorelaxation of 
vascular smooth muscle (VSM) cells. In VSM, hyperpolarisation causes closure of VGCC, 
decreasing intracellular Ca2+ and eliciting vasorelaxation. Various mechanisms lead to 
hyperpolarisation of VSM, including efflux of K+ through VSM K+ channels and EDHF. The 
EDHF pathway consists of an initial increase in intracellular calcium in endothelial cells 
which causes VSM hyperpolarisation via various pathways, including transfer of 
hyperpolarisation via gap junctions, or release of diffusible factors from endothelium which 
activate BKCa and KATP channels on VSM. NO and PGI2, are produced in endothelial cells 
before diffusing to adjacent smooth muscle cells to increase cGMP and cAMP levels, 
respectively, thus causing vasorelaxation. Activation of Cl-/HCO3- exchange on VSM causes 
intracellular acidification, which reduces the open probability of VGCC, causing 
vasorelaxation. [AA, arachidonic acid; VSM, vascular smooth muscle; VGCC, voltage-gate 
calcium channels; EDHF, endothelial derived hyperpolarizing factor; NO, nitric oxide; PGI2, 
prostacyclin; NOS, nitric oxide synthase; COX, cyclo-oxygenase; cAMP, cyclic adenosine 
monophosphate; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; 
ATP, adenosine triphosphate VSM; vascular smooth muscle]. 
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1.3 Regulation of blood pressure 
The multivariable mechanisms controlling the blood pressure can be categorized into intrinsic 
and extrinsic control mechanisms, which can be further subdivided into local control 
mechanisms and hormonal control mechanisms. Cardiac performance and vascular tone at 
any time are the result of the integration of all the control mechanisms. To some extent, this 
categorization can be described as artificial because each categories affects the other. 
1.3.1 Extrinsic Mechanisms 
The extrinsic control systems consist of the sympathetic nervous system (SNS), 
parasympathetic nervous system (PNS), and the circulating hormones which contribute to the 
regulation of BP and blood volume. 
1.3.1.1 Nervous System 
The nervous system plays a vital role in the short-term regulation of blood pressure BP. The 
BP regulatory center is located in the medulla. Previous findings have shown that autonomic 
innervations of blood vessels provide a tight regulation of blood pressure within a narrow 
range (Joyner et al., 2008). Blood vessels are primarily innervated with sympathetic nerve 
fibers while the heart receives both sympathetic and parasympathetic innervations (Thomas 
and Segal, 2004). Activation of the sympathetic nervous system (SNS) leads to an increase 
in the vascular smooth muscle (VSM) tone resulting in vasoconstriction of both the resistance 
and capacitance vessels. This leads to an increase in total peripheral resistance (TPR). SNS 
activation also increases the heart rate (HR) and force of contraction, and also causes renin 
release (McCorry, 2007). Current researches have indicated hyperactivity of the SNS as a 
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possible index and pathogenesis on the development of essential hypertension (Svarstad et 
al., 2001) and other cardiovascular diseases (Malpas, 2010; Parati and Esler, 2012). 
1.3.1.2 Humoral Systems 
The humoral system regulates BP mainly through the renin angiotensin aldosterone system 
(RAAS), and other mediators described below. 
1.3.1.2.1 Renin Angiotensin Aldosterone System 
RAAS is an endocrine system that plays an integral role in controlling the hemodynamic state 
of the body and arterial blood pressure primarily via the regulation of body fluid. Changes in 
the pump function, coronary blood flow and systemic arterial compliance underlie the role of 
the RAAS on the cardiovascular system in maintaining circulatory integrity (Brewster et al., 
2003). Decrease in renal perfusion in the kidney due to low BP leads to the release of the 
proteolytic enzyme called Renin from the juxtaglomerular cells (Atlas, 2007; Rao, 2010). 
Renin cleaves an inactive peptide angiotensinogen (alpha 2 globulin circulating in the blood) 
to derive angiotensin I (Ang I). Ang I is converted to angiotensin II (Ang II) by an enzyme 
found in lung capillaries called angiotensin-converting-enzyme (ACE). Ang II is an effective 
vasoconstrictor. Ang II acts as an agonist in an endocrine, paracrine, autocrine and 
intracranial fashion (Ellis et al., 2012). Ang II stimulates the secretion of aldosterone from 
the adrenal cortex. Aldosterone influences the kidney tubules to retain sodium and water. 
This increases the blood volume which contributes to an increase in BP. RAAS hormonal 
system responds to low blood volume or a fall in BP (Gwathmey et al., 2012). 
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1.3.1.2.2 Arginine Vasopressin System 
Arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is a nonapeptide 
protein which is derived from a prehormone synthesized in hypothalamus and stored in the 
posterior pituitary gland (Birnbaumer, 2000). AVP plays a pivotal role in the reabsorption of 
water from the collecting ducts in the kidney via activation of V2 receptors (Nakamura et al., 
2006). At pharmacological doses, AVP exerts a profound vasoconstriction by activating V1 
receptors found on vascular smooth muscle cells (VSMC). Stimulation of AVP release is 
triggered by an increase in osmolality (Robertson, 2006), rise in arterial blood pressure, fall 
in blood volume, and decrease in venous return . 
1.3.1.2.3 Atrial Natriuretic Peptide 
Atrial natriuretic peptide (ANP) is a 28 amino acid polypeptide hormone produced and 
secreted by cardiomyocytes of the atria of the heart (Horio et al., 2000; Kumar and Pandey, 
2009). It is released in response to atrial stretch, stretching of the vessel walls, stimulation of 
beta receptors, hypervolemia, hypernatremia, elevation in Ang II and following exercise. It 
exerts both, a natriuretic and a vasodilatory effect. The overall effect of ANP is to counter 
RAAS mediated increase in BP (Park et al., 2015). 
1.3.1.2.4 Oubain like Factor 
Oubain-like factor (OLF) is an endogenous substance that is indistinguishable from the 
digitalis glycoside, oubain. It has been found circulating in blood (Manunta et al., 2001). This 
substance inhibits Na+/K+ activated ATPase and induces natriuresis and vasoconstriction. 
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OLF is released in response to high sodium intake, hypervolemia and in conditions of 
cardiovascular disease state such as hypertension (Manunta et al., 2009). 
1.3.2 Intrinsic Mechanisms 
Intrinsic system regulates blood flow mainly within the tissue/organ or remains restricted to 
specific regional vascular beds. This mechanism includes myogenic mechanism which refers 
to the property of the muscle tissue to respond to stretch. It is likely that metabolic and 
humoral mechanisms contribute to the regulation of blood flow as an intrinsic control system 
(Guyenet, 2006). In addition to the extrinsic and the intrinsic regulatory mechanisms, the 
endothelium is now widely recognized as a one of the major regulators of BP and blood flow. 
The endothelium can be considered as an endocrine organ in its own right and can be 
considered as a part of the humoral systems of regulation or as a separate system. 
1.3.2.1 Endothelium 
The endothelium is the thin layer of cells that forms the inner intima lining of the blood 
vessels (Aird, 2007a). Thus, the endothelium is an interface between the lumen and the rest 
of the vessel wall. These cells are present in the circulatory system, beginning from the heart 
to the smallest capillaries. Endothelial cells (EC) are specialized epithelium called simple 
squamous epithelium. EC are very important for the regulation of various functions such as 
vasodilatation, vasoconstriction, thrombosis, fibrinolysis, angiogenesis, inflammation and 
edema (Aird, 2007b). All of these factors contribute to the overall BP regulation by the 
endothelium. Transit of white blood cells into and out of the blood is controlled by the EC 
The endothelium synthesizes and secretes a number of vasodilator such as EDHF, PGI2 and 
NO (Martin, 2009). Carbon monoxide (Thorup et al., 1999) and hydrogen sulfide (H2S) 
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(Yang et al., 2008) have also been added to the list of vasodilator mediators released from 
the endothelium, and vasoconstrictor; Endothelin (Sugden, 2003)  and thromboxane A2 
(Félétou et al., 2010). This vasoactive mediators play a role in the cardiovascular regulatory 
functions of endothelium. Thus, the endothelium plays an important role in the regulation of 
vascular tone (Sandoo et al., 2010) and by extension the regulation of blood pressure.  
Moreover, other blood borne mediators and mediators released from nerves act on the 
endothelium, platelets and vascular smooth muscle to regulate vascular tone, platelet 
function, capillary permeability and other cardiovascular functions. These mediators include 
angiotensin II (Ang II), norepineprine, histamine, bradykinin, 5-hydroxytryptamine (5-HT) 
thromboxane and acetylcholine. In a physiological state there is a balance between these 
vasoconstrictor and vasodilator agents. In disease states such as hypertension and diabetes, 
this balance is disturbed due to altered bioavailability of one or more of the endothelial 
mediators such as NO (Rajendran et al., 2013). . 
1.4 Phytochemical and pharmacological review of Alstonia scholaris 
Alstonia scholaris (L.) R. Br., a genus of the family apocynaceae, is a glabrous, evergreen 
tree native of the Indian subcontinent and Southeast Asia.  It has been well documented for 
its folklore uses in the prevention and treatment of various diseases (Baliga, 2012; Bhanu et 
al., 2013; Dey, 2011). 
1.4.1 Plant Profile 
Botanical name → Alstoniascholaris 
Kingdom → Plantae  
Order → Gentianale 
Family →Apocynaceae 
Genus → Alstonia 
Species → Alstonia scholaris 
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Alstonia scholaris is widely used in traditional medicinal systems of India, Thailand, 
Malaysia, Philippines, Australia, China and Africa (Cunningham and Read, 2003; Laidlaw et 
al., 2007; Rai, 1994). The genus Alstonia comprises of more than 60 species all over the 
world.  
Alstonia scholaris is known with numerous names such as devil's tree, white cheese wood, 
mill wood, milkwood pines, kilky pine, black board tree and dita bark (English). It was 
initially named Echites scholaris by Linnaeus in 1767 (Khyade et al., 2014). In the year 1811, 
the plant was renamed as Alstonia by Robert Brown in the memory of Professor Charles 
Alston. The name of species scholaris was derived from the use of its wood in making 
blackboards for schools in South East Asia (Baliga, 2012). 
1.4.2 Morphological characteristics 
Alstonia scholaris is a medium to large tree of about 40 m height with somewhat tessellated 
corky grey to grey-white bark with bitter milky juice. The outer blaze is cream yellowish in 
color with abundant, milky latex that flows rapidly when cut. The Leaves are whorls of 4-8 
in the upper axils, obtuse or sometimes shortly and bluntly acuminate, dark green above, pale 
and covered with a whitish bloom beneath (Figure 1.4). The Flowers are white, in umbellately 
branched many-flowered pubescent capitates cymes; peduncles 2.5-5 cm long; pedicels very 
short; bracts oblong, pubescent. Seeds are 6 mm long, linear, flattened, rounded and with a 
fringe of hairs at both ends, the hairs longer than the seed. 
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Figure 1.4: Depiction of Alstonia scholaris. (A) Leave (B) flower (C) the trunk 
Bark and (D) the fruit. 
1.4.3 Phytochemical studies 
Over the past decades, different extracts of Alstonia scholaris have been studied extensively 
for their numerous phytochemical constituents that play a crucial role in its pharmacological 
and medicinal properties. An estimate of more than four hundred important phytoconstituents 
have been isolated and characterized from different part of the plant. Alkaloids, iridoids, 
coumarins, flavonoids, leucoanthocyanines, reducing sugars, simple phenolics steroids, 
saponins and tannins were documented as the chief chemical constituents. Alstonia scholaris 
contains some of the important alkaloids such as echitamine, tubotaiwine (stem and root 
bark), akuammine (root bark) and so on (Khyade, et al., 2014; Pratap et al., 2013b).  
 
A 
B D 
C 
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Table 1.1: Chemical structures of some important phytochemical constituents 
isolated from Alstonia scholaris L. 
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1.4.4 Ethnopharmacological properties 
Alstonia scholaris has been widely used for treatment of a wide range of ailments and 
extensive pharmacological studies have been documented to explore, evaluate and validate 
its vast pharmacological potentials. The plant has been investigated for its anti-inflammatory 
and analgesic effects (Shang et al., 2010a);  anticancer (Jagetia and Baliga, 2004a; 2006; 
Jahan et al., 2009; Manjeshwar Shrinath, 2010); antimalarial ; antimicrobial (Bonvicini et al., 
2014; Mahapatra and Banerjee, 2010); antifungal and antiviral (Antony et al., 2014; Antony 
et al., 2012); antifertility (Gupta et al., 2002); antibacterial (Ganjewala and Gupta, 2013; 
Khan et al., 2003; Molly et al., 2014); anti-arthritic (Arulmozhi et al., 2011; 2014); 
antihyperglycemic (El-Askary et al., 2013; Khatun et al., 2009; Ragasa et al., 2013); 
antidiabetic and antihyperlipidemic (Arulmozhi et al., 2010b; Jong-Anurakkun et al., 2007); 
antidiarrhoeal and antispasmodic (Keawpradub et al., 1999; Shah et al., 2010); antimutagenic 
(Jagetia et al., 2003); anti-anxiety (Arulmozhi et al., 2008); Antineoplastic (Jagetia and 
Baliga, 2003a; 2005), anti-ulcerogeni (Ashok et al., 2006); wound healing (Ramachandra et 
al., 2012); nitric oxide scavenging (Jagetia and Baliga, 2004b); immunostimulating effect 
(Atmaram et al., 2012; Iwo et al., 2000); radioprotective (Gupta et al., 2008; Jagetia and 
Baliga, 2003b; Jahan and Goyal, 2010); antiaging effects on the skin (Lee et al., 2012; Saikia 
et al., 2006), anti-tussive, anti-asthmatic and expectorant activities (Shang et al., 2010b), 
hepatoprotective effect ; neuroleptic activity (Jash and Chowdary, 2014), broncho-
vasodilatory activity (Channa et al., 2005). Kulkarni and Juvekar (2009) reported the anti-
stress (adaptogenic) and nootropic activities of methanolic extract of bark of Alstonia 
scholaris. The antioxidant and free radical scavenging profile has also been documented 
(Arulmozhi et al., 2007; 2010c; Asadujjaman et al., 2013; Kumar et al., 2010).  
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Some phytochemical constituents isolated from Alstonia scholaris have been assayed for 
their pharmacological activity. Macabeo et al. (2008) studied the inhibitory effect of four 
alkaloids of Alstonia scholaris  against myobacterium tuberculosis. Strictamine has been 
reported to have neuropharmacological and antidepressive effect (Bhattacharya et al., 1979). 
The allelopatic effect of pantacyclictriterpenoids such as betulinic acid, oleanolic acid, and 
ursolic acid has also been investigated (Wang et al., 2014). 17-nor-excelsinidine, a novel 
alkaloid isolated from the twigs and leaves of Alstonia scholaris alongside strictamine 
showed significant inhibitory activity against herpes simplex virus (HSV) and adenovirus 
(ADV) (Zhang et al., 2014). Echitamine from Alstonia scholaris has shown significant 
antitumor activity (Kamarajan et al., 1991). In Ayurveda, the bitter and astringent concoction 
of the leave is used as a herb for treating skin disorders, malarial fever, urticaria, chronic 
dysentery, diarrhea and snake bite. The bark contains alkaloids, ditamine, echitenine and 
echitamine and used to serve as an alternative to quinine. Bark is use as appetizer, laxative, 
anthelmintic and galactagogue. The tenders’ leaves roasted and pulverized is also useful in 
ulcers with foul discharge (Ashok Kumar et al., 2014).  
1.4.5 Rationale and objectives of the present study 
Despite the large volume of pharmacological data on the medicinal properties of Alstonia 
scholaris available, many of the diseases treated traditionally using the plant have not been 
validated in the laboratory. This provide an opportunity to study the specie both 
pharmacologically and phytochemically. Therefore, ethnopharmacology can bridge the gap 
between the traditional use and actual pharmacological veracity and efficacy of the medicinal 
plant. The objectives of this research is outlined as follows; 
